Atlas Capital Advisors Inc. Has $70,000 Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Atlas Capital Advisors Inc. grew its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 400.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,440 shares of the company’s stock after acquiring an additional 3,552 shares during the quarter. Atlas Capital Advisors Inc.’s holdings in Dr. Reddy’s Laboratories were worth $70,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Townsquare Capital LLC acquired a new stake in Dr. Reddy’s Laboratories in the 3rd quarter valued at about $286,000. Quantinno Capital Management LP increased its holdings in shares of Dr. Reddy’s Laboratories by 18.0% in the third quarter. Quantinno Capital Management LP now owns 20,237 shares of the company’s stock valued at $1,608,000 after purchasing an additional 3,094 shares in the last quarter. State Street Corp raised its position in Dr. Reddy’s Laboratories by 1.9% in the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock worth $72,292,000 after purchasing an additional 16,641 shares during the last quarter. Orion Portfolio Solutions LLC lifted its holdings in Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 20,524 shares of the company’s stock worth $1,631,000 after buying an additional 6,192 shares in the last quarter. Finally, EWA LLC acquired a new position in Dr. Reddy’s Laboratories during the 3rd quarter worth $899,000. 3.85% of the stock is owned by institutional investors.

Dr. Reddy’s Laboratories Trading Down 6.6 %

RDY opened at $12.37 on Friday. The firm has a 50 day simple moving average of $13.33 and a 200 day simple moving average of $14.50. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $12.36 and a fifty-two week high of $16.89. The company has a market cap of $10.32 billion, a price-to-earnings ratio of 19.69 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.